Search results
Results from the WOW.Com Content Network
Factor V Leiden (rs6025 or F5 p.R506Q [1]) is a variant (mutated form) of human factor V (one of several substances that helps blood clot), which causes an increase in blood clotting (hypercoagulability).
14067 Ensembl ENSG00000198734 ENSMUSG00000026579 UniProt P12259 O88783 RefSeq (mRNA) NM_000130 NM_007976 RefSeq (protein) NP_000121 NP_032002 Location (UCSC) Chr 1: 169.51 – 169.59 Mb Chr 1: 163.98 – 164.05 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Coagulation factor V (Factor V), also less commonly known as proaccelerin or labile factor, is a protein involved in ...
In factor V Leiden, a G1691A nucleotide replacement results in an R506Q amino acid mutation. Factor V Leiden increases the risk of venous thrombosis by two known mechanisms. First, activated protein C normally inactivates factor Va by cleaving the cofactor at Arg 306, Arg 506, and Arg 679. [24] The factor V Leiden mutation at Arg 506 renders ...
For premium support please call: 800-290-4726 more ways to reach us
Factor V Leiden is responsible for 8% of cases. [2] Other less common inherited disorders leading to the condition include factor II mutation (3%), protein C deficiency (5%), protein S deficiency (4%), and antithrombin III deficiency(1%). [2] [14] Budd–Chiari syndrome may be the presenting sign of these hypercoagulable disorders.
The minor ("type 2") thrombophilias are much more common. Factor V Leiden is present in 5% of the population of Northern European descent, but much rarer in those of Asian or African extraction. In people with thrombosis, 10% have factor V Leiden. In those who are referred for thrombophilia testing, 30–50% have the defect.
The initial treatment for VTE is typically either low-molecular-weight heparin ... Factor V Leiden [7] Prothrombin G20210A [7] Dysfibrinogenemia [9] Non O-blood type [21]
Heterozygous for factor V Leiden mutation; Heterozygous for factor II mutation; Overweight, in this case defined as a BMI > 28 at early pregnancy [9] Caesarean section; DVT heredity in a first-degree relative; Age > 40 years; Pre-eclampsia; Hyperhomocysteinemia; 2 points Intermediate risk factors: Protein S or protein C deficiency